Released Aug 8, 2019, before the open
10-Q filed Aug 8, 2019, 39 days after period end · 0001144204-19-038552
Q2 2019 · 10-Q
Revenue$12.25M$12.25M +510.5% vs Q2 2018+17.3% vs Q1 2019
Net Income-$7.74M-$7.74M N/M vs Q2 2018N/M vs Q1 2019
EPS Diluted-$0.52-$0.52 N/M vs Q2 2018N/M vs Q1 2019
Operating Income-$5,839,000N/M
Operating Cash Flowderived-$5,170,000N/M
Free Cash Flowderived-$5,207,000N/M
Margins · derived
Operating margin-47.7%+288.5 pt vs Q2 2018
Net margin-63.2%+358.6 pt vs Q2 2018
What the release said
The release
Same quarter
| Metric | Q2 2019 | Q2 2018 | Q2 2017 | Q2 2016 |
|---|---|---|---|---|
| Revenue | $12.25M | $2.01M | $6.36M | $1.77M |
| Net Income | -$7.74M | -$8.46M | $450.00K | -$10.85M |
| EPS Diluted | -$0.52 | -$0.06 | -$0.06 | -$0.11 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR